Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8605695 | Journal of Pain and Symptom Management | 2018 | 33 Pages |
Abstract
Although not superior to placebo on the primary efficacy endpoint, nabiximols had benefits on multiple secondary endpoints, particularly in the U.S. patients. Nabiximols might have utility in patients with advanced cancer who receive a lower opioid dose, such as individuals with early intolerance to opioid therapy.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Aron H. PhD, Eberhard Albert MD, Robert PhD, Sandro MD, Raymond MD, Wei PhD, Stephen MD, MA, Elena MD, PhD, Marie T. MB, ChB, MD,